European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
暂无分享,去创建一个
C. Schiffer | R. Larson | M. Baccarani | R. Clark | H. Kantarjian | J. Cortes | M. Deininger | J. Lipton | D. Niederwieser | R. Silver | G. Saglio | J. Richter | J. Janssen | P. Rousselot | F. Mahon | S. Soverini | F. Pane | R. Hehlmann | A. Hochhaus | F. Guilhot | M. Deininger | F. Nicolini | T. Hughes | H. Hjorth-Hansen | F. Cervantes | J. Apperley | G. Rosti | J. Mayer | J. Radich | S. Saussele | J. Steegmann | D. Réa | A. Zaritskey | A. Turkina | C. Schiffer | D. Kim | F. Mahon | Dong-Kee Kim | J. Mayer | T. Hughes | A. Hochhaus | Susanne Saussele | Ruediger Hehlmann | Jane F. Apperley | S. Saussele | R. Hehlmann | Susanne Saußele | J. Apperley
[1] Jinny Park,et al. Long‐term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE) , 2020, British journal of haematology.
[2] S. Pileri,et al. Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study. , 2019, Blood.
[3] B. Druker,et al. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. , 2019, The New England journal of medicine.
[4] J. Radich,et al. Meeting the needs of CML patients in resource-poor countries. , 2019, Hematology. American Society of Hematology. Education Program.
[5] I. Flinn,et al. Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis , 2019, Blood.
[6] R. Foà,et al. Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial , 2019, Blood.
[7] T. Brümmendorf,et al. Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study , 2019, Blood.
[8] C. Craddock,et al. FLAG-IDA and Ponatinib in Patients with Blast Phase Chronic Myeloid Leukaemia: Results from the Phase I/II UK Trials Acceleration Programme Matchpoint Trial , 2019, Blood.
[9] T. Brümmendorf,et al. High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels , 2019, Blood.
[10] S. Fujiwara,et al. Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation. , 2019, Blood advances.
[11] B. Kramer,et al. Epidemiologic Signatures in Cancer. , 2019, The New England journal of medicine.
[12] J. Lipton,et al. The role of ponatinib in chronic myeloid leukemia in the era of treatment free remission , 2019, Leukemia & lymphoma.
[13] H. Kantarjian,et al. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study. , 2019, The Lancet. Haematology.
[14] J. Byrne,et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. , 2019, The Lancet. Haematology.
[15] J. Lipton,et al. The true value of second-generation TKIs as first-line therapy in chronic myeloid leukaemia. , 2019, The Lancet. Haematology.
[16] J. Reynolds,et al. Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib. , 2019, Blood advances.
[17] G. Mufti,et al. Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study. , 2019, The Lancet. Haematology.
[18] J. Byrne,et al. Initial reduction of therapy prior to complete treatment discontinuation in chronic myeloid leukaemia: final results of the British DESTINY Study , 2019 .
[19] U. Olsson‐Strömberg,et al. Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry , 2019, Bone Marrow Transplantation.
[20] A. Turkina,et al. Risks and challenges of CML management during pregnancy: Looking for a balanced decision , 2019, European journal of haematology.
[21] Z. Estrov,et al. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. , 2019, Blood advances.
[22] M. Baccarani,et al. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview , 2019, Leukemia.
[23] C. Tam,et al. The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia , 2019, Leukemia & lymphoma.
[24] J. Hasford,et al. Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV , 2018, Haematologica.
[25] T. Brümmendorf,et al. Pregnancy outcomes in patients treated with bosutinib , 2018, International journal of hematologic oncology.
[26] M. Mauro,et al. Back to the future: Treatment‐free remission and pregnancy in chronic myeloid leukemia , 2018, European journal of haematology.
[27] J. Wason,et al. Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML , 2018, Blood.
[28] R. Foà,et al. Outcome of 472 Chronic Myeloid Leukemia Patients Treated with Frontline Nilotinib: A Gimema CML WP Analysis , 2018, Blood.
[29] R. Foà,et al. The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly Chronic Myeloid Leukemia Patients , 2018, Blood.
[30] J. Gribben,et al. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. , 2018, The Lancet. Haematology.
[31] C. Cleeland,et al. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second‐ and third‐generation tyrosine kinase inhibitors , 2018, Cancer medicine.
[32] H. Kantarjian,et al. Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value , 2018, Cancer.
[33] J. Radich,et al. Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.
[34] Anna L. Brown,et al. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. , 2018, Blood.
[35] J. Cortes,et al. Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia , 2018, Haematologica.
[36] Martin C. Müller,et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. , 2018, Blood.
[37] Martin C. Müller,et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. , 2018, The Lancet. Oncology.
[38] G. Chilov,et al. Breastfeeding in Patients with Chronic Myeloid Leukaemia: Case Series with Measurements of Drug Concentrations in Maternal Milk and Literature Review , 2018, Mediterranean journal of hematology and infectious diseases.
[39] N. Thielen,et al. Validation of the EUTOS long-term survival score in a recent independent cohort of “real world” CML patients , 2018, Leukemia.
[40] J. Pinilla-Ibarz,et al. Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study , 2018, Annals of Hematology.
[41] T. McDonnell,et al. Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy. , 2017, Blood advances.
[42] A. Salihoglu,et al. Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec , 2017, Clinical lymphoma, myeloma & leukemia.
[43] M. Konopleva,et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients , 2017, Cancer.
[44] T. Brümmendorf,et al. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] T. Brümmendorf,et al. Long‐term patient‐reported outcomes from an open‐label safety and efficacy study of bosutinib in Philadelphia chromosome–positive chronic myeloid leukemia patients resistant or intolerant to prior therapy , 2017, Cancer.
[46] S. Swerdlow. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .
[47] Sukjoong Oh,et al. Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia , 2017, Clinical Cancer Research.
[48] T. Brümmendorf,et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants , 2017, Leukemia.
[49] B. Leber,et al. Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results , 2017, Leukemia.
[50] C. Gambacorti-Passerini,et al. Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis. , 2017, European journal of cancer.
[51] J. Góra‐Tybor,et al. Quality of Life and Adherence to Therapy in Patients With Chronic Myeloid Leukemia Treated With Nilotinib as a Second‐Line Therapy: A Multicenter Prospective Observational Study , 2017, Clinical lymphoma, myeloma & leukemia.
[52] A. Kurtovic-Kozaric,et al. The Efficacy of Generic Imatinib as First‐ and Second‐line Therapy: 3‐Year Follow‐up of Patients With Chronic Myeloid Leukemia , 2017, Clinical lymphoma, myeloma & leukemia.
[53] Francisco Cervantes,et al. Long‐Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia , 2017, The New England journal of medicine.
[54] P. Carlier,et al. Erratum to: Pregnancy outcome among partners of male patients receiving imatinib, dasatinib or nilotinib in chronic myeloid leukemia: reports collected by the French network pharmacovigilance centers , 2017, Archives of Gynecology and Obstetrics.
[55] M. Baccarani,et al. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? , 2017, Nature Reviews Clinical Oncology.
[56] W. Wiktor-Jedrzejczak,et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study , 2017, Leukemia.
[57] M. Tulliez,et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. , 2017, Blood.
[58] M. Tulliez,et al. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] U. Olsson‐Strömberg,et al. Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era – a report from the Swedish CML register , 2017, European journal of haematology.
[60] F. Efficace,et al. The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors. , 2016, Hematology. American Society of Hematology. Education Program.
[61] Aaron N. Winn,et al. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] Paul W Dickman,et al. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] Jeroen J. Bax,et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines , 2016, European journal of heart failure.
[64] G. Lip,et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). , 2016, European heart journal.
[65] R. Silver,et al. Management of CML-blast crisis. , 2016, Best practice & research. Clinical haematology.
[66] M. Baccarani,et al. Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. , 2016, Leukemia research.
[67] P. Cony-Makhoul,et al. CML patients show sperm alterations at diagnosis that are not improved with imatinib treatment. , 2016, Leukemia research.
[68] U. Olsson‐Strömberg,et al. Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients , 2016, Leukemia.
[69] N. Thielen,et al. Chronic myeloid leukemia in the Netherlands: a population‐based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012 , 2016, European journal of haematology.
[70] T. Hughes,et al. Moving treatment-free remission into mainstream clinical practice in CML. , 2016, Blood.
[71] H. Kantarjian,et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. , 2016, Blood.
[72] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[73] J. Richter,et al. The concept of treatment-free remission in chronic myeloid leukemia , 2016, Leukemia.
[74] M. Baccarani,et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] T. Clackson,et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. , 2016, The Lancet. Oncology.
[76] M. Baccarani,et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia , 2016, Leukemia.
[77] Martin C. Müller,et al. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States , 2016, Journal of the National Cancer Institute.
[78] I. Flinn,et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial , 2016, Leukemia.
[79] N. Cordani,et al. Chronic myeloid leukemia: Second‐line drugs of choice , 2016, American journal of hematology.
[80] S. Mustjoki,et al. Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients , 2015 .
[81] S. Aksu,et al. Generic Imatinib Mesylate is as Effective as Original Glivec in the Clinical Management of CML , 2015 .
[82] J. Sakamoto,et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. , 2015, The Lancet. Haematology.
[83] J. Cortes,et al. The impact of dasatinib on pregnancy outcomes , 2015, American journal of hematology.
[84] N. Schmitz,et al. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment , 2015, Leukemia.
[85] W. Wiktor-Jedrzejczak,et al. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study , 2015, Leukemia.
[86] Martin C. Müller,et al. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML , 2015, Annals of Hematology.
[87] Martin C. Müller,et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. , 2015, Blood.
[88] F. Gherlinzoni,et al. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib , 2015, Leukemia.
[89] M. Konopleva,et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. , 2015, The Lancet. Haematology.
[90] M. Baccarani,et al. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. , 2015, Blood.
[91] C. Preudhomme,et al. Analyzing molecular response in chronic myeloid leukemia clinical trials: Pitfalls and golden rules , 2015, Cancer.
[92] K. Spiekermann,et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV , 2015, Leukemia.
[93] D. Colomer,et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia , 2015, Leukemia.
[94] P. Valent,et al. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. , 2015, Blood.
[95] M. Baccarani,et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries , 2015, Leukemia.
[96] M. Baccarani,et al. Gimema Registry of Conception/Pregnancy in Adult Patients Diagnosed with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs) , 2014 .
[97] M. Baccarani,et al. Impact of Dose Intensity of Ponatinib on Selected Adverse Events: Multivariate Analyses from a Pooled Population of Clinical Trial Patients , 2014 .
[98] U. Olsson‐Strömberg,et al. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006) , 2014, European journal of haematology.
[99] B. Leber,et al. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. , 2014, Blood.
[100] U. Olsson‐Strömberg,et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[101] J. Hasford,et al. Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase , 2014, Journal of Cancer Research and Clinical Oncology.
[102] T. Brümmendorf,et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. , 2014, Blood.
[103] Martin C. Müller,et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[104] J. Cayuela,et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[105] Aaron N. Winn,et al. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. , 2014, Journal of Clinical Oncology.
[106] M. Baccarani,et al. Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden , 2014, Haematologica.
[107] H. Kantarjian,et al. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia , 2014, Cancer.
[108] T. Clackson,et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. , 2013, The New England journal of medicine.
[109] Francisco Cervantes,et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. , 2013, Blood.
[110] H. Jim,et al. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison , 2013, Supportive Care in Cancer.
[111] J. Cortes,et al. Re-emergence of interferon-α in the treatment of chronic myeloid leukemia , 2012, Leukemia.
[112] Suzanne Kamel-Reid,et al. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. , 2012, Blood.
[113] N. Cross,et al. Standardized definitions of molecular response in chronic myeloid leukemia , 2012, Leukemia.
[114] T. Brümmendorf,et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[115] Shah Ebrahim,et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.
[116] D. Marin,et al. Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation , 2012, Haematologica.
[117] Arnon Nagler,et al. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. , 2011, Blood.
[118] J. Hasford,et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. , 2011, Blood.
[119] A. Kohlmann,et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases , 2011, Leukemia.
[120] Claude Preudhomme,et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. , 2010, The New England journal of medicine.
[121] J. Radich,et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[122] J. Apperley. Issues of imatinib and pregnancy outcome. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.
[123] N. Cross. Standardisation of molecular monitoring for chronic myeloid leukaemia. , 2009, Best practice & research. Clinical haematology.
[124] G. Boysen,et al. European Guidelines on Cardiovascular Disease Prevention , 2009, International journal of stroke : official journal of the International Stroke Society.
[125] Martin C. Müller,et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. , 2008, Blood.
[126] A. Ganser,et al. Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia , 2007, Leukemia.
[127] Francisco Cervantes,et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2006, Blood.
[128] Simona Soverini,et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. , 2006, Blood.
[129] Francisco Cervantes,et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.
[130] J. Hasford,et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. , 1998, Journal of the National Cancer Institute.
[131] Francisco Cervantes,et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia , 1984 .
[132] A S Spiers,et al. METAMORPHOSIS OF CHRONIC GRANULOCYTIC LEUKAEMIA: DIAGNOSIS, CLASSIFICATION, AND MANAGEMENT , 1979, British journal of haematology.
[133] Z. Estrov,et al. Long‐term follow‐up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic‐phase chronic myeloid leukemia , 2019, Cancer.
[134] H. Khoury,et al. Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017. , 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[135] H. Khoury,et al. Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017. , 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[136] M. Baccarani,et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia , 2016, Leukemia.
[137] A. Hoes,et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. , 2016, Revista espanola de cardiologia.
[138] P. Cony-Makhoul,et al. Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study. , 2015, The Lancet. Haematology.
[139] J. Radich,et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study , 2013, Leukemia.
[140] A. Hoes,et al. [Guidelines on cardiovascular disease prevention in clinical practice]. , 2005, Revue medicale de Liege.
[141] H. Heimpel,et al. Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia – prospective long-term results from a randomized-controlled trial , 2003, Leukemia.
[142] M. Baccarani,et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. , 1984, Blood.